The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Nurix Therapeutics Inc’s stock clocked out at $11.88, down -0.08% from its previous closing price of $11.89. In other words, the price has decreased by -$0.08 from its previous closing price. On the day, 0.8 million shares were traded. NRIX stock price reached its highest trading level at $12.33 during the session, while it also had its lowest trading level at $11.78.
Ratios:
To gain a deeper understanding of NRIX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.82 and its Current Ratio is at 6.82. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 17, 2025, initiated with a Market Perform rating and assigned the stock a target price of $16.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $35.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $35.BMO Capital Markets initiated its Outperform rating on December 06, 2024, with a $35 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 30 ’25 when van Houte Hans sold 4,304 shares for $12.01 per share. The transaction valued at 51,695 led to the insider holds 40,914 shares of the business.
Ring Christine sold 3,841 shares of NRIX for $46,134 on Jul 30 ’25. The Chief Legal Officer now owns 44,009 shares after completing the transaction at $12.01 per share. On Jul 30 ’25, another insider, Hansen Gwenn, who serves as the Chief Scientific Officer of the company, sold 4,308 shares for $12.01 each. As a result, the insider received 51,743 and left with 69,023 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 908218880 and an Enterprise Value of 474368352. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.28 while its Price-to-Book (P/B) ratio in mrq is 2.03. Its current Enterprise Value per Revenue stands at 5.367 whereas that against EBITDA is -2.135.
Stock Price History:
The Beta on a monthly basis for NRIX is 2.15, which has changed by -0.44666976 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is 1.75%, while the 200-Day Moving Average is calculated to be -26.67%.
Shares Statistics:
It appears that NRIX traded 864.87K shares on average per day over the past three months and 773750 shares per day over the past ten days. A total of 76.43M shares are outstanding, with a floating share count of 74.92M. Insiders hold about 2.00% of the company’s shares, while institutions hold 110.31% stake in the company. Shares short for NRIX as of 1752537600 were 13946880 with a Short Ratio of 16.13, compared to 1749772800 on 14435008. Therefore, it implies a Short% of Shares Outstanding of 13946880 and a Short% of Float of 21.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Nurix Therapeutics Inc (NRIX) is currently in progress, with 15.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.76 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$2.72 and -$3.24 for the fiscal current year, implying an average EPS of -$2.96. EPS for the following year is -$3.65, with 15.0 analysts recommending between -$1.97 and -$4.51.
Revenue Estimates
A total of 16 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $112.96M, while the lowest revenue estimate was $62.5M, resulting in an average revenue estimate of $93.74M. In the same quarter a year ago, actual revenue was $54.55M
